Abstract
Editorials1 October 1990Myopathy with Human Immunodeficiency Virus Type 1 (HIV-1) Infection: HIV-1 or Zidovudine?Michele Till, MD, Keith B. MacDonell, MDMichele Till, MDSearch for more papers by this author, Keith B. MacDonell, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-7-492 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRecent data indicate that early therapy with zidovudine is beneficial in slowing disease progression in persons infected with the human immunodeficiency virus type 1 (HIV-1) when CD4 cell counts are less than 500 cells/ mm3(1). Many persons infected with HIV-1 will be taking zidovudine over long periods, and clinicians may be faced with related complications. One such complication is the development of a drug-induced myopathy. Although muscle pathologies including inflammatory myopathy (2-5), type II atrophy (6), and nemaline rod myopathy (2, 7, 8) had been described in association with HIV-1 infection before use of zidovudine, there are now several...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
